Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Blood (2025) 146 (Supplement 1): 470.

https://doi.org/10.1182/blood-2025-470

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

Blood (2025) 146 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2025-3676

Published: 2025

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Pavel Otahal, MD PhD, Andrea Janikova, MD PhD Assoc Prof, David Belada, MD PhD, Vit Prochazka, MD, Heidi Mocikova, MD PhD, Jan Pirnos, Juraj Ďuraš, Kateřina Kopečková, Vit Campr, MD PhD, Robert Pytlik, Petra Blahovcova, Mgr, Marek Trneny, MD CSc

Blood (2018) 132 (Supplement 1): 5413.

https://doi.org/10.1182/blood-2018-99-117110

Published: 2018

Journal Articles

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Andrea Janikova, MD PhD, Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD PhD, Zbynek Bortlicek, PhD, Vit Campr, MD PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD PhD, Michaela Hamouzova, David Belada, MDPhD, Vit Prochazka, MD PhD ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, Marek Trneny

Blood (2016) 128 (22): 3000.

https://doi.org/10.1182/blood.V128.22.3000.3000

Published: 2016

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Andrea Janikova, MD, PhD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Leos Kren, MD, PhD, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Jan Pirnos, MD, Milan Matuska, MD, PhD, Tomas Papajik, MD, PhD, ass. prof., Heidi Mocikova, MD, PhD, Samuel Vokurka, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4387.

https://doi.org/10.1182/blood.V122.21.4387.4387

Published: 2013

Journal Articles

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Andrea Janikova, MD, PhD, Katerina Benesova, MD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Natasa Kopalova, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Samuel Vokurka, MD, PhD, Jan Pirnos, MD, Milan Matuska, MD, PhD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4388.

https://doi.org/10.1182/blood.V122.21.4388.4388

Published: 2013

Journal Articles

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

Blood (2010) 116 (21): 2882.

https://doi.org/10.1182/blood.V116.21.2882.2882

Published: 2010

Journal Articles

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Marek Trneny, MD, PhD, Robert Pytlik, MD, David Belada, MD, PhD., Katerina Kubackova, MD, Milada Jankovska, MD, Tomas Papajik, MD., PhD., Jan Pirnos, MD, Hana Krejcova

Blood (2008) 112 (11): 1014.

https://doi.org/10.1182/blood.V112.11.1014.1014

Published: 2008

Journal Articles

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

David Salek, MD, Ingrid Vasova, MD, Robert Pytlik, MD, David Belada, MD, PhD, Tomas Papajik, MD, PhD, Katerina Kubackova, MD, Jan Pirnos, MD, Ludmila Boudova, MD, PhD, Roman Kodet, MD, Petra Obrtlikova, MD, Hana Krejcova, Marek Trneny, MD, PhD

Blood (2008) 112 (11): 3745.

https://doi.org/10.1182/blood.V112.11.3745.3745

Published: 2008

Journal Articles

Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.

Marek Trneny, Robert Pytlik, David Belada, Katerina Kubackova, Ingrid Vasova, Alice Sykorova, Tomas Kozak, Jan Pirnos, Milan Matuska, Ingrid Bolomska, Jana Pribylova, Marie Trnkova, Michaela Hamouzova, Pavel Klener

Blood (2007) 110 (11): 21.

https://doi.org/10.1182/blood.V110.11.21.21

Published: 2007

Journal Articles

Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies.

Robert Pytlik, David Belada, Katerina Kubackova, Tomas Kozak, PhD, Milada Jankovska, Jan Pirnos, Ingrid Bolomska, Ingrid Vasova, Tomas Papajik, Alena Sykorova, Hana Siffnerova, Michaela Hamouzova, Pavel Klener, Marek Trneny

Blood (2006) 108 (11): 4692.

https://doi.org/10.1182/blood.V108.11.4692.4692

Published: 2006

Journal Articles

Treatment of High Risk Diffuse Large B-Cell Lymphomas (DLBCL) with Ntensive Induction Chemotherapy, Rituximab and Autologous Stem Cell Transplant.

Robert Pytlik, Marek Trneny, David Belada, Jan Pirnos, Katerina Kubackova, Milada Jankovska, Ingrid Vasova, Tomas Kozak, Jana Pukyova, Jana Pribylova, Hana Siffnerova, Pavel Zak, Michaela Hamouzova, Pavel Klener

Blood (2005) 106 (11): 1506.

https://doi.org/10.1182/blood.V106.11.1506.1506

Published: 2005

Journal Articles

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Marek Trneny, MD, David Belada, MD, Ingrid Vasova, MD, Robert Pytlik, MD, Tomas Kozak, MD, Alice Sykorova, MD, Katerina Kubackova, MD, Jan Pirnos, MD, Ingrid Bolomska, MD, Marketa Petrova, Ing

Blood (2005) 106 (11): 2444.

https://doi.org/10.1182/blood.V106.11.2444.2444

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.

Intensive Induction Is Beneficial for High Risk Younger Patients with Aggressive B-Cell Lymphoma, While Frontline ASCT Brings No Benefit: Final Analysis of MegaCHOP-BEAM and MegaCHOP-ESHAP-BEAM Studies.

Treatment of High Risk Diffuse Large B-Cell Lymphomas (DLBCL) with Ntensive Induction Chemotherapy, Rituximab and Autologous Stem Cell Transplant.

Rituximab Combination with Anthracyclin Based Chemothrapy Significantly Improved the Outcome of Young Patients with Diffuse Large B-Cell Lymphoma in Low as Well in High Risk Subgroups.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only